MounjaroTirzepatide for type 2 diabetes + obesity in India 2026
by Eli Lilly · ₹14,000–27,500/month · DCGI approved March 2025 (DCGI/CDSCO marketing authorisation)
| Active ingredient | Tirzepatide (Dual GIP and GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Eli Lilly and Company |
| DCGI status | Approved March 2025 (DCGI/CDSCO marketing authorisation) |
| Price (MRP) | ₹14,000–27,500/month Premium pricing reflects patent-protected status. No generic tirzepatide is expected in India before approximately 2036. |
| Format | Prefilled KwikPen (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly) · Single-dose vial |
| Prescription | Schedule H — required |
How Mounjaro compares
Mounjaro is Eli Lilly's brand of tirzepatide — a different molecule from semaglutide that activates both GIP and GLP-1 receptors. The SURMOUNT-1 trial showed approximately 22% mean weight loss versus semaglutide's 15.3% in STEP 1, and the SURMOUNT-5 head-to-head suggests tirzepatide produces greater weight loss. DCGI approved Mounjaro in March 2025 for both type 2 diabetes and obesity. Premium pricing reflects patent protection — no Indian generic tirzepatide is expected before approximately 2036.
About Eli Lilly
Eli Lilly is the manufacturer behind Mounjaro and Zepbound. Mounjaro became India's top-selling drug by value in October 2025, generating ₹333 crore in cumulative sales since its March 2025 launch — one of the fastest scale-ups for any new injectable antidiabetic in India. Lilly's pipeline includes additional dual and triple agonist obesity drugs.
Who is Mounjaro for?
Mounjaro is approved in India for both type 2 diabetes and chronic weight management in adults with obesity. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication). Patients with BMI ≥25 + comorbidities (PCOS, NAFLD, hypertension, sleep apnea) may also qualify under specialist judgment.
Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →
Mounjaro for specific conditions
Mounjaro cost in India
MRP for Mounjaro: ₹14,000–27,500/month. Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.
Full dose-by-dose pricing + hidden costs (consults, labs, needles): Mounjaro price in India 2026 →
Compared to other GLP-1 brands in India
Mounjaro is Eli Lilly's tirzepatide — a dual GIP + GLP-1 agonist, distinct molecule from semaglutide. SURMOUNT and SURPASS trials show tirzepatide typically achieves greater HbA1c and weight reductions than semaglutide brands, but at higher cost. For semaglutide alternatives, see Ozempic, Wegovy, or any Indian generic.
Mounjaro — frequently asked questions
Is Mounjaro available in India? Is it DCGI-approved?+
What does Mounjaro cost in India in 2026?+
Do I need a prescription to buy Mounjaro?+
Who is Mounjaro for?+
How does Mounjaro compare to semaglutide brands?+
Where can I buy Mounjaro in India?+
Manufacturer announcement
Additional source
Reuters / Yahoo Finance — Mounjaro India launchGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.